DE69841206D1 - Polymere vorstufenwirkstoffe von amino-und hydroxyl-enthaltenden bioaktiven agentien - Google Patents

Polymere vorstufenwirkstoffe von amino-und hydroxyl-enthaltenden bioaktiven agentien

Info

Publication number
DE69841206D1
DE69841206D1 DE69841206T DE69841206T DE69841206D1 DE 69841206 D1 DE69841206 D1 DE 69841206D1 DE 69841206 T DE69841206 T DE 69841206T DE 69841206 T DE69841206 T DE 69841206T DE 69841206 D1 DE69841206 D1 DE 69841206D1
Authority
DE
Germany
Prior art keywords
substituted
alkyls
cycloalkyls
aryls
heteroalkyls
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69841206T
Other languages
English (en)
Inventor
Richard B Greenwald
Annapurna Pendri
Yun H Choe
Samuel Zalipsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enzon Pharmaceuticals Inc
Original Assignee
Enzon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Inc filed Critical Enzon Inc
Priority claimed from PCT/US1998/026565 external-priority patent/WO1999030727A1/en
Application granted granted Critical
Publication of DE69841206D1 publication Critical patent/DE69841206D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyamides (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69841206T 1997-12-17 1998-12-14 Polymere vorstufenwirkstoffe von amino-und hydroxyl-enthaltenden bioaktiven agentien Expired - Lifetime DE69841206D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99243597A 1997-12-17 1997-12-17
US09/183,557 US6180095B1 (en) 1997-12-17 1998-10-30 Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
PCT/US1998/026565 WO1999030727A1 (en) 1997-12-17 1998-12-14 Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents

Publications (1)

Publication Number Publication Date
DE69841206D1 true DE69841206D1 (de) 2009-11-12

Family

ID=25538340

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69841206T Expired - Lifetime DE69841206D1 (de) 1997-12-17 1998-12-14 Polymere vorstufenwirkstoffe von amino-und hydroxyl-enthaltenden bioaktiven agentien

Country Status (4)

Country Link
US (1) US6180095B1 (de)
EP (1) EP1897561A1 (de)
AT (1) ATE444080T1 (de)
DE (1) DE69841206D1 (de)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100361933B1 (ko) * 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
AU1825299A (en) * 1997-12-17 1999-07-05 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
PL206536B1 (pl) 1998-10-16 2010-08-31 Biogen Idec Inc Kompozycja, kompozycja farmaceutyczna glikozylowanego interferonu-beta-1a, zastosowanie kompozycji glikozylowanego interferonu-beta-1a, sposób in vitro przedłużania aktywności glikozylowanego interferonu-beta-1a
CA2343094A1 (en) * 1998-10-16 2000-04-27 Biogen, Inc. Interferon-beta fusion proteins and uses
US6458953B1 (en) * 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
AU769425B2 (en) * 1999-04-23 2004-01-29 Alza Corporation Conjugate having a cleavable linkage for use in a liposome
US6713454B1 (en) * 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
CA2412162A1 (en) * 2000-07-12 2002-01-17 Gryphon Therapeutics, Inc. Chemokine receptor modulators, production and use
CA2412277A1 (en) * 2000-09-08 2002-03-14 Gryphon Therapeutics, Inc. Synthetic erythropoiesis stimulating proteins
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
DE60223496T2 (de) * 2001-02-20 2008-10-02 Enzon, Inc. Endgruppenverzweigte polymere verbindungsgruppen und diese enthaltende polymere konjugate
DE60233315D1 (de) 2001-03-23 2009-09-24 Enzon Inc Prodrugs von krebsmitteln mit substituierten aromatischen säuren
US20040077835A1 (en) * 2001-07-12 2004-04-22 Robin Offord Chemokine receptor modulators, production and use
CA2952488C (en) * 2002-01-18 2019-05-07 Biogen Ma Inc. Polyalkylene glycol with moiety for conjugating biologically active compounds
EP1534823A4 (de) * 2002-07-12 2008-12-31 Biomarin Pharm Inc Verwendung von isocyanatlinkern zur herstellung von hydrolysierbaren wirkstoff-biopolymer-konjugaten
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
WO2004043396A2 (en) * 2002-11-09 2004-05-27 Nobex Corporation Modified carbamate-containing prodrugs and methods of synthesizing same
US7462687B2 (en) * 2002-11-12 2008-12-09 Enzon Pharmaceuticals, Inc. Prodrugs of vancomycin with hydrolysis resistant polymer linkages
WO2004061094A1 (en) 2002-12-30 2004-07-22 Gryphon Therapeutics, Inc. Water-soluble thioester and selenoester compounds and methods for making and using the same
EP1597299A2 (de) * 2003-02-19 2005-11-23 Pharmacia Corporation Mit oxalatestern aktivierte carbonatester von polyethylenglykol
US7332164B2 (en) * 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
JP5209204B2 (ja) * 2003-04-13 2013-06-12 エンゾン ファーマスーティカルズ インコーポレイテッド ポリマーオリゴヌクレオチドプロドラッグ
WO2005039489A2 (en) * 2003-09-24 2005-05-06 Polymerix Corporation Compositions and methods for the inhibition of bone growth and resorption
CA2551495A1 (en) * 2004-01-07 2005-07-28 Ambit Biosciences Corporation Conjugated small molecules
EP1807436B1 (de) * 2004-10-25 2014-06-18 Intezyne Technologies Inc. Heterobifunktionelles poly(ethylenglykol) und seine verwendungen
EP2314320A2 (de) 2005-04-05 2011-04-27 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Verfahren zur Abschirmung von funktionalen Stellen oder Epitopen von Proteinen
WO2007079404A2 (en) * 2005-12-30 2007-07-12 Pharmaessentia Corp. Drug-polymer conjugates
GB0604187D0 (en) * 2006-03-02 2006-04-12 Fusion Antibodies Ltd Peptide and uses thereof
CA2650035C (en) 2006-04-27 2015-02-03 Intezyne Technologies, Inc. Poly (ethylene glycol) containing chemically disparate endgroups
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
US7632492B2 (en) * 2006-05-02 2009-12-15 Allozyne, Inc. Modified human interferon-β polypeptides
GB0611405D0 (en) * 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
EP2035016A2 (de) * 2006-06-09 2009-03-18 Enzon Pharmaceuticals, Inc. Indenoisochinolin-lösliche polymer-konjugate
CA2652718A1 (en) * 2006-06-30 2008-01-24 Enzon Pharmaceuticals, Inc. Recombinant host for producing l-asparaginase ii
CA2662520A1 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates containing positively-charged moieties
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
EP2120966A4 (de) * 2006-11-27 2013-06-19 Enzon Pharmaceuticals Inc Polymere konjugate mit kurzer interferierender rna
US20080159964A1 (en) * 2006-12-29 2008-07-03 Enzon Pharmaceuticals, Inc. Use of adenosine deaminase for treating pulmonary disease
SI2147122T1 (sl) * 2007-04-20 2015-01-30 Sigma-Tau Pharma Limited Encimatska terapija proti raku
SI2147116T1 (sl) 2007-04-20 2016-06-30 Sigma-Tau Rare Disease Ltd. Stabilna rekombinantna adenozin-deaminaza
WO2009009716A1 (en) * 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Polymeric drug delivery systems containing an aromatic allylic acid
WO2009009712A1 (en) * 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Polymeric drug delivery system containing a multi-substituted aromatic moiety
CA2707840A1 (en) * 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
ES2885698T3 (es) 2009-06-25 2021-12-15 Alkermes Pharma Ireland Ltd Profármacos de compuestos nh-ácidos
CA2766088C (en) 2009-06-25 2017-06-13 Alkermes, Inc. Heterocyclic compounds for the treatment of neurological and psychological disorders
ES2647361T3 (es) * 2010-01-07 2017-12-21 Alkermes Pharma Ireland Limited Profármacos de sales de amonio cuaternario
US20110166128A1 (en) * 2010-01-07 2011-07-07 Alkermes, Inc. Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders
US20110166194A1 (en) * 2010-01-07 2011-07-07 Alkermes, Inc. Asenapine Prodrugs
US20110166156A1 (en) * 2010-01-07 2011-07-07 Alkermes, Inc. Prodrugs for the Treatment of Schizophrenia and Bipolar Disease
ES2768295T3 (es) 2010-01-07 2020-06-22 Alkermes Pharma Ireland Ltd Profármacos de compuestos heteroaromáticos
CA2802733C (en) 2010-06-24 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
AU2011325990C1 (en) * 2010-11-12 2017-06-08 Nektar Therapeutics Conjugates of an IL-2 moiety and a polymer
EP3536695A1 (de) 2010-12-13 2019-09-11 QuiaPEG Pharmaceuticals AB Funktionalisierte polymere
BR112013014115A2 (pt) * 2010-12-29 2019-09-24 Arrowhead Res Corporation conjugados de fornecimento de polinucleotídeos in vivo apresentando ligações enzimáticas sensíveis
FI3156056T3 (fi) 2011-03-18 2024-03-01 Alkermes Pharma Ireland Ltd Sorbitaaniestereitä käsittäviä farmaseuttisia koostumuksia
DE102011118029A1 (de) 2011-06-20 2012-12-20 Universität Leipzig Modifizierte antibiotische Peptide mit variabler systemischer Freisetzung
US9150846B2 (en) 2011-07-05 2015-10-06 Bioasis Technologies, Inc. P97-antibody conjugates and methods of use
WO2013088255A1 (en) 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
EP2827868B8 (de) 2012-03-19 2019-12-18 Alkermes Pharma Ireland Limited Pharmazeutische zusammensetzungen mit fettsäureestern
ES2950418T3 (es) 2012-03-19 2023-10-09 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden alcohol bencílico
CA2867123C (en) 2012-03-19 2021-02-16 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising water-insoluble antipsychotic agents and glycerol esters
EP3628332A1 (de) 2012-06-12 2020-04-01 QuiaPEG Pharmaceuticals AB Konjugate biologisch aktiver moleküle an funktionalisierte polymere
WO2014022515A1 (en) 2012-07-31 2014-02-06 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
JP6654042B2 (ja) 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド 貯蔵安定性が改善された医薬組成物
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
AU2013344464A1 (en) 2012-11-16 2015-05-21 The Regents Of The University Of California Pictet-Spengler ligation for protein chemical modification
NZ711373A (en) 2013-03-13 2020-07-31 Bioasis Technologies Inc Fragments of p97 and uses thereof
AU2014312190A1 (en) 2013-08-28 2016-02-18 Bioasis Technologies Inc. CNS-targeted conjugates of antibodies
AU2014354643B2 (en) 2013-11-27 2020-03-05 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
MX370138B (es) 2014-02-26 2019-12-03 Univ Texas Liberación de protones de nitrobenzaldehído para la manipulación de la acidosis celular.
CA2943213C (en) 2014-03-20 2022-07-05 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
CA2964317C (en) 2014-10-14 2021-10-05 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
BR112018009225A2 (pt) 2015-11-09 2019-02-05 Scherer Technologies Llc R P conjugados de anticorpo anti-cd22-maitansina e métodos de uso dos mesmos
EP4019007A1 (de) 2016-06-01 2022-06-29 Servier IP UK Limited Formulierungen von polyalkylen-oxid-asparaginase und verfahren zur herstellung und verwendung davon
KR20220150408A (ko) 2016-11-14 2022-11-10 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
CN108727208B (zh) * 2017-03-07 2020-06-30 天津键凯科技有限公司 一种连接子化合物、聚乙二醇-连接子结合物及其衍生物和聚乙二醇-连接子-药物结合物
CN110545850A (zh) 2017-03-10 2019-12-06 奎亚培格制药公司 可释放的缀合物
JP7022328B2 (ja) 2017-03-30 2022-02-18 日油株式会社 自壊性アセタールリンカーを有する親水性ポリマー誘導体及びそれを用いた複合体
US10391154B2 (en) 2017-07-19 2019-08-27 Leadiant Biosciences Ltd. Compositions and methods for treating or ameliorating fibrosis, systemic sclerosis and scleroderma
ES2951817T3 (es) 2017-08-22 2023-10-25 Dynavax Tech Corp Derivados de imidazoquinolina de cadena alquílica modificada como agonistas de TLR7/8 y usos de los mismos
CN109589415B (zh) * 2017-09-30 2022-02-18 天津键凯科技有限公司 一种聚乙二醇-多肽和蛋白类药物的结合物
CN114668852A (zh) * 2017-09-30 2022-06-28 天津键凯科技有限公司 一种聚乙二醇-多肽和蛋白类药物的结合物
WO2019099412A1 (en) 2017-11-14 2019-05-23 Dynavax Technologies Corporation Cleavable conjugates of tlr7/8 agonist compounds, methods for preparation, and uses thereof
WO2019133399A1 (en) 2017-12-26 2019-07-04 Becton, Dickinson And Company Deep ultraviolet-excitable water-solvated polymeric dyes
EP3761983A1 (de) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Dosierstrategie für aripiprazol
JP2021519841A (ja) 2018-03-30 2021-08-12 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ ペンダントクロモフォアを有する水溶性ポリマー色素
EP3813867A1 (de) 2018-07-22 2021-05-05 Bioasis Technologies Inc. Behandlung von lymphatischen metastasen
WO2020053815A1 (en) 2018-09-12 2020-03-19 Quiapeg Pharmaceuticals Ab Releasable glp-1 conjugates
EP3909612A1 (de) 2020-05-12 2021-11-17 Life Science Inkubator Betriebs GmbH & Co. KG Zusammensetzung von nanopartikeln
US20210355468A1 (en) 2020-05-18 2021-11-18 Bioasis Technologies, Inc. Compositions and methods for treating lewy body dementia
US20210393787A1 (en) 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
EP3954393A1 (de) 2020-08-13 2022-02-16 Bioasis Technologies Inc. Kombinationstherapien zur verabreichung über die blut-hirn-schranke hinweg
EP4155349A1 (de) 2021-09-24 2023-03-29 Becton, Dickinson and Company Wasserlösliche gelbe grünabsorbierende farbstoffe
WO2024007016A2 (en) 2022-07-01 2024-01-04 Beckman Coulter, Inc. Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
WO2024044327A1 (en) 2022-08-26 2024-02-29 Beckman Coulter, Inc. Dhnt monomers and polymer dyes with modified photophysical properties
WO2024196805A1 (en) 2023-03-17 2024-09-26 Beckman Coulter, Inc. Benzothienopyrrole cyanine dyes

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JP2958019B2 (ja) 1988-05-06 1999-10-06 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
FR2676058B1 (fr) 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
JP3026133B2 (ja) * 1992-11-05 2000-03-27 コニカ株式会社 ハロゲン化銀写真感光材料
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
DE69425356T2 (de) * 1993-09-22 2002-04-18 Hoechst Ag Pro-Prodrugs, ihre Herstellung und Anwendung
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5672584A (en) 1995-04-25 1997-09-30 The University Of Kansas Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability
EP0751144B1 (de) 1995-06-27 2004-10-06 Pharmachemie B.V. Anthracyclin Prodrugs, Verfahren zu deren Herstellung und deren Verwendung in der selektiven Chemotherapie
EP0961619A4 (de) 1996-09-27 2001-09-26 Bristol Myers Squibb Co Hydrolisierbare prodrugs zur verabreichung von wirkstoffen gegen krebs an metastatische zellen
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents

Also Published As

Publication number Publication date
US6180095B1 (en) 2001-01-30
EP1897561A1 (de) 2008-03-12
ATE444080T1 (de) 2009-10-15

Similar Documents

Publication Publication Date Title
DE69841206D1 (de) Polymere vorstufenwirkstoffe von amino-und hydroxyl-enthaltenden bioaktiven agentien
CA2312975A1 (en) Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
EP1041995A4 (de) Trialkyl-blockierung-vereinfachte polymerische medikamentenvorstufen von aminogruppen enthaltenden bioaktiven substanzen
DK0581452T3 (da) Vaskemiddelsammensætninger med polysuccinimid
ATE102966T1 (de) Blockcopolyester mit verzweigten hydrophilen endgruppen, verwendbar als schmutzentfernungsmittel in waschmittelzusammensetzungen.
DE69739853D1 (de) Synthetische rapamycinderivate als multimerisierende wirkstoffe für chimere proteine mit von immunophilin abgeleiteten domänen
BR9809390A (pt) Polìmeros biodegradáveis estendidos com cadeia de fosfatos, composições, artigos e método para fazer e usar os mesmos.
ES2132886T3 (es) Polimerizacion en presencia de un radical nitroxido beta-substituido.
CY1105811T1 (el) Ενωσεις ενισχυτη ταξολης
DE69816051D1 (de) Zusammensetzungen und verfahren zur hemmung der licht-induzierten inaktivierung von biologischen reagenzien
FR2774899B1 (fr) Composition cosmetique a base de polyurethannes associatifs et de polymeres non ioniques a chaines grasses
NO950957D0 (no) PNA-syntese ved anvendelse av en labil amino-beskyttelsesgruppe
WO2007063030A3 (de) Verwendung von kammpolymeren als mahlhilfsmittel für zementhaltige zubereitungen
ATE157362T1 (de) N-pyridyl carboxamidderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutischen zusammensetzungen
ES2056146T3 (es) Monopersulfatos de acidos amino-(poli)percarboxilicos.
DE60233315D1 (de) Prodrugs von krebsmitteln mit substituierten aromatischen säuren
DE59707524D1 (de) 1,3-bis-(n-lactamyl)propane und deren pharmazeutische und kosmetische verwendung
ATE238549T1 (de) Phosphatase-aktivierte quervernetzende konjugierende und reduzierende agenzien, verfahren unter verwendung solcher agenzien und reagenzien die phosphatase-aktivierte quervernetzende und konjugierende agenzien enthalten
BR0014371A (pt) Misturas de polìmeros contendo poliésteres modificados
ATE203510T1 (de) Multifunktionelle vinylcyclopropan-derivate
AR036866A1 (es) Diamidodioles, metodo para sintetizar un diamidodiol, metodo para preparar un diacido y metodo para sintetizar un macrociclo de tetraamido
ES2160136T3 (es) Polimeros que contienen aminas y productos de los mismos.
DE60112946D1 (de) Harzzusammensetzung
EP0573873A3 (en) Process for the preparation of urethane or urea groups-containing compact or cellular elastomers or mouldings thereof
CA2033444A1 (en) Production of elastic, compact or cellular moldings based on elastomers containing n-benzylurea groups in bound form, elastomers of this type, and n-benzylpolyoxyalkylene-polyamines which are suitable for this purpose

Legal Events

Date Code Title Description
8364 No opposition during term of opposition